Skip to Content

Bempedoic acid Approval Status

FDA Approved: No
Generic name: bempedoic acid
Company: Esperion Therapeutics, Inc.
Treatment for: High Cholesterol, Familial Heterozygous

Bempedoic acid is a first-in-class, ATP Citrate Lyase (ACL) inhibitor in development for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).

Bempedoic acid reduces cholesterol biosynthesis and lowers LDL-C by up-regulating the LDL receptor. Similar to statins, bempedoic acid also reduces hsCRP, a key marker of inflammation associated with cardiovascular disease.

Development Status and FDA Approval Process for bempedoic acid

DateArticle
May  5, 2019Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
Mar 13, 2019Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
Jan  8, 2017Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid
Jun 28, 2016Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide